India · Delayed Price · Currency is INR Aurobindo Pharma Statistics
Total Valuation
NSE:AUROPHARMA has a market cap or net worth of INR 925.21 billion. The enterprise value is 900.01 billion.
| Market Cap | 925.21B |
| Enterprise Value | 900.01B |
Important Dates
The last earnings date was Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:AUROPHARMA has 575.38 million shares outstanding. The number of shares has decreased by -0.25% in one year.
| Current Share Class | 575.38M |
| Shares Outstanding | 575.38M |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 15.38% |
| Owned by Institutions (%) | 31.42% |
| Float | 273.38M |
Valuation Ratios
The trailing PE ratio is 25.13 and the forward PE ratio is 19.64. NSE:AUROPHARMA's PEG ratio is 1.22.
| PE Ratio | 25.13 |
| Forward PE | 19.64 |
| PS Ratio | 2.65 |
| PB Ratio | 2.44 |
| P/TBV Ratio | 2.82 |
| P/FCF Ratio | 32.57 |
| P/OCF Ratio | 16.74 |
| PEG Ratio | 1.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.68, with an EV/FCF ratio of 31.68.
| EV / Earnings | 24.24 |
| EV / Sales | 2.58 |
| EV / EBITDA | 12.68 |
| EV / EBIT | 16.84 |
| EV / FCF | 31.68 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.14 |
| Debt / FCF | 2.84 |
| Interest Coverage | 15.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 10.35% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 4.26% |
| Revenue Per Employee | 11.96M |
| Profits Per Employee | 1.27M |
| Employee Count | 29,209 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:AUROPHARMA has paid 17.09 billion in taxes.
| Income Tax | 17.09B |
| Effective Tax Rate | 31.54% |
Stock Price Statistics
The stock price has increased by +47.56% in the last 52 weeks. The beta is 0.02, so NSE:AUROPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | +47.56% |
| 50-Day Moving Average | 1,560.75 |
| 200-Day Moving Average | 1,345.02 |
| Relative Strength Index (RSI) | 51.63 |
| Average Volume (20 Days) | 986,382 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:AUROPHARMA had revenue of INR 349.35 billion and earned 37.13 billion in profits. Earnings per share was 63.99.
| Revenue | 349.35B |
| Gross Profit | 205.60B |
| Operating Income | 53.48B |
| Pretax Income | 54.20B |
| Net Income | 37.13B |
| EBITDA | 70.21B |
| EBIT | 53.48B |
| Earnings Per Share (EPS) | 63.99 |
Balance Sheet
The company has 105.85 billion in cash and 80.73 billion in debt, with a net cash position of 25.12 billion or 43.66 per share.
| Cash & Cash Equivalents | 105.85B |
| Total Debt | 80.73B |
| Net Cash | 25.12B |
| Net Cash Per Share | 43.66 |
| Equity (Book Value) | 378.83B |
| Book Value Per Share | 652.39 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 55.26 billion and capital expenditures -26.86 billion, giving a free cash flow of 28.41 billion.
| Operating Cash Flow | 55.26B |
| Capital Expenditures | -26.86B |
| Depreciation & Amortization | 16.73B |
| Net Borrowing | -6.93B |
| Free Cash Flow | 28.41B |
| FCF Per Share | 49.37 |
Margins
Gross margin is 58.85%, with operating and profit margins of 15.31% and 10.63%.
| Gross Margin | 58.85% |
| Operating Margin | 15.31% |
| Pretax Margin | 15.51% |
| Profit Margin | 10.63% |
| EBITDA Margin | 20.10% |
| EBIT Margin | 15.31% |
| FCF Margin | 8.44% |
Dividends & Yields
This stock pays an annual dividend of 8.00, which amounts to a dividend yield of 0.49%.
| Dividend Per Share | 8.00 |
| Dividend Yield | 0.49% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.25% |
| Shareholder Yield | 0.73% |
| Earnings Yield | 4.01% |
| FCF Yield | 3.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:AUROPHARMA is 1,678.32, which is 4.37% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,678.32 |
| Price Target Difference | 4.37% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 12.48% |
| EPS Growth Forecast (3Y) | 18.94% |
Stock Splits
The last stock split was on July 20, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Jul 20, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |